Osage University Partners

Osage University Partners
Private ownership
Industry Venture Capital
Founded 2011
Headquarters Philadelphia, Pennsylvania, United States
Website www.osageuniversitypartners.com

Osage University Partners (OUP) is a venture capital fund specializing in university spinouts. OUP has partnerships with 50+ affiliated universities, national labs, and research institutions. The fund invests in all stages of development including seed, early, and late stage. General partners include Robert Adelson, Bill Harrington,[1] Marc Singer, and founding partner Louis Berneman. OUP is part of Osage Partners,[2] a family of investment funds with diversified investment strategies including Osage Venture Partners.[3]

Investment Strategy

Osage University Partners invests across all sectors of university commercialization, including Information Technology, Energy, Materials, and Life Science. The fund invests across all stages, including seed, early, and late. OUP closed its first fund in 2011, a $100 million fund from diverse institutional investors.[4] The fund promotes the venture and entrepreneurship ecosystems around universities, typically co-investing with other leading venture capital firms.

Participation Rights

Through their licensing activities, universities and research institutions generally have the right (a “Participation Right”) to invest in their own spin-outs. Historically, few universities or research institutions have exercised such rights. OUP utilizes these rights to invest in university spinouts, and in return universities and research institutions share in the fund’s profits.[5]

OUP seeks to make investments by primarily exercising the Participation Rights of its partner universities, and if no formal Participation Right exists, to participate as a co-investor on behalf of the university or research institution.[6]

Affiliated Institutions

Portfolio Companies

Portfolio companies include, Aerie Pharmaceuticals, AGTC, Atterocor, Avid Radiopharmaceuticals, Cardioxyl, Cleave Biosciences, Clinipace Worldwide, Corridor Pharmaceuticals, Gevo (NASDAQ: GEVO), Guardant Health, Immune Design, Koltan Pharmaceuticals, Kymeta,[7] Liquid Light, Luxtera, MC10, Mirna Therapeutics, Otonomy,[8] Receptos (NASDAQ: RCPT), Sera Prognostic, Skytree, SolarBridge Technologies, Tangent Medical, and Urjanet

See also

References

External links

This article is issued from Wikipedia - version of the Thursday, March 31, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.